Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
HUYA Japan to Transfer Hiyasta Marketing Authorization to Meiji
Meiji Seika Pharma said on November 30 that it took over the Japanese marketing authorization (MA) for the cancer drug Hiyasta (tucidinostat) from HUYA Japan, effective the same day. An oral histone deacetylase (HDAC) inhibitor, Hiyasta was approved in Japan…
To read the full story
Related Article
- Meiji’s Hiyasta Earns Approval in Thailand
July 21, 2026
- HUYA’s Hiyasta Enters PIII Melanoma Study in Japan: Meiji
April 26, 2023
- Meiji to Launch Japan PIb/II of Hiyasta for B-cell Non-Hodgkin’s Lymphoma
December 23, 2021
- Meiji Pharma Rolls Out ATLL Drug Hiyasta in Japan
October 21, 2021
BUSINESS
- Lilly Confirms Orforglipron Diabetes Filings in US, Japan
August 7, 2026
- Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
- Inrebic Expands First-Line Treatment Options for Myelofibrosis: Expert
August 7, 2026
- Meiji Pharma Drops Hiyasta Development in B-Cell NHL
August 7, 2026
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…